#1
#1 out of 195.52%
health3h ago
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
- NHS England approves Elahere for FRα-positive, platinum-resistant ovarian cancer, offering a new option for hard-to-treat cases.
- The drug mirvetuximab soravtansine, known as Elahere, targets FRα and combines antibody with a cancer-killing molecule.
- NICE’s assessment supported the approval, with a new commercial arrangement with AbbVie.
- Up to 400 women a year in England could benefit from the treatment.
- The trial showed tumor shrinkage in a substantial subset of patients.
- Elahere combines a targeting antibody with a cancer-killing payload to attack cancer cells.
- NHS England’s clinical lead called the approval the most significant breakthrough in over two decades.
- Experts anticipate improved quality of life for patients despite treatment burdens.
- Elahere is administered every three weeks as part of the treatment regimen.
Vote 0